Just as a disciplined a soccer player might pass on a hopeful shot in favor of a better chance later on, the biopharma venture capital market reflected a preference for de-risked assts over platforms ...
In 2025, Moderna spent $3.1 billion on R&D, a 31% decrease from the $4.5 billion budget (PDF) in 2024 and a further drop from ...
The FDA has rejected a rare blood disease candidate from Disc Medicine, a compound that been granted expedited review through ...
BridgeBio is hoping infigratinib will get another shot at approval after the medicine hit the key goals of a phase 3 study in ...
"The FDA rejected Moderna's application for filing because the company refused to follow very clear FDA guidance from 2024 to ...
Madrigal Pharmaceuticals is continuing to splash the cash this year on liver disease drugs it can combine with its own ...
One month after Integra LifeSciences recalled its wound and burn devices amid safety concerns, the medtech company is cutting ...
Just months after laying off a quarter of its workforce to fund a phase 2 study of its bloodstream infection preventive ...
Ultragenyx Pharmaceutical's employees were already braced for changes as the biopharma considered how to rebound from a pair ...
Takeda’s real estate downsize will add to the region’s growing office sublease market. A January 2026 CBRE report on the ...
A phase 2 asthma study of Upstream Bio’s TSLP receptor agonist has hit its primary endpoint. But with only the 12-week ...
Nektar Therapeutics is basking in the honeyed glow of long-term phase 2 data for its immune asset rezpegaldesleukin in atopic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results